If Richard Padzur retires, he would become one of several high-ranking FDA officials who left the agency in 2025.

On 1 December, the fortunes of the UK pharma sector changed radically, with the UK Government becoming the first in the world ...

Citizen Health has entered a multi-year strategic partnership with UCB for expediting drug development across five rare ...

AGC Biologics is set to expand its Cell Line Development Centre of Excellence through a partnership with ATUM.

New non-primate draft guidance follows the FDA's wider aim to curtail the use of animal testing in preclinical toxicology.

Biotechs in the charter city of Próspera aim to cure ageing, but experts question the feasibility of their goals.

Rare disease research faces complex regulations, small patient populations, and high costs. As traditional incentives wane, ...

Data management in oncology clinical trials features multiple complexities, and choosing the right EDC system is essential.

The World Health Organization (WHO) predicts that fewer than 10% of eligible patients will have access to GLP-1RAs by 2030.

As 2026 approaches, rising complexity, geopolitical pressures and new modalities are reshaping strategy, capacity and CDMO ...

With $1.5 billion in drug sales, the US dominated the CKD-HPT, HP and HK market in 2024, representing 59.7% of 7MM sales.

The UK becomes the latest country in President Donald Trump’s long line of trade agreements, though it is the first region to ...